Synapse - Mark Kris

Results (869)

Non-small cell lung cancer: Clinical practice guidelines in oncology

Journal Article

Ettinger, D. S.; Akerley, W.; Borghaei, H.; Chang, A. C.; Cheney, R. T.; Chirieac, L. R.; D'Amico, T. A.; Demmy, T. L.; Ganti, A. K. P.; Govindan, R.; more...
Journal of the National Comprehensive Cancer Network (2012)

Fulltext@MSK | Save

Distinct clinical course of EGFR-mutant resected lung cancers: Results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib

Journal Article

D'Angelo, S. P.; Janjigian, Y. Y.; Ahye, N.; Riely, G. J.; Chaft, J. E.; Sima, C. S.; Shen, R.; Zheng, J.; Dycoco, J.; Kris, M. G.; more...
Journal of Thoracic Oncology (2012)

Fulltext@MSK | Save

Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers

Meeting Abstract

Kris, M.; Goldberg, Z.; Jänne, P. A.; Kim, D.; Martins, R.; Mok, T. S. K.; O'Connell, J.; Ou, S.; Taylor, I.; Zhang, H.
Annals of Oncology (2012)

Fulltext@MSK | Save

HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation

Journal Article

Takezawa, K.; Pirazzoli, V.; Arcila, M. E.; Nebhan, C. A.; Song, X.; de Stanchina, E.; Ohashi, K.; Janjigian, Y. Y.; Spitzler, P. J.; Melnick, M. A.; more...
Cancer Discovery (2012)

Fulltext@MSK | Save

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component

Journal Article

Paik, P. K.; Varghese, A. M.; Sima, C. S.; Moreira, A. L.; Ladanyi, M.; Kris, M. G.; Rekhtman, N.
Molecular Cancer Therapeutics (2012)

Fulltext@MSK | Save

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas

Journal Article

Paik, P. K.; Johnson, M. L.; D'Angelo, S. P.; Sima, C. S.; Ang, D.; Dogan, S.; Miller, V. A.; Ladanyi, M.; Kris, M. G.; Riely, G. J.
Cancer (2012)

Fulltext@MSK | Save

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers

Journal Article

Dogan, S.; Shen, R.; Ang, D. C.; Johnson, M. L.; D'Angelo, S. P.; Paik, P. K.; Brzostowski, E. B.; Riely, G. J.; Kris, M. G.; Zakowski, M. F.; more...
Clinical Cancer Research (2012)

Fulltext@MSK | Save

When progressive disease does not mean treatment failure: Reconsidering the criteria for progression

Journal Article

Oxnard, G. R.; Morris, M. J.; Hodi, F. S.; Baker, L. H.; Kris, M. G.; Venook, A. P.; Schwartz, L. H.
JNCI: Journal of the National Cancer Institute (2012)

Fulltext@MSK | Save

Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung

Journal Article

Chaft, J. E.; Sima, C. S.; Ginsberg, M. S.; Huang, J.; Kris, M. G.; Travis, W. D.; Azzoli, C. G.
Journal of Thoracic Oncology (2012)

Fulltext@MSK | Save

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas

Journal Article

Arcila, M. E.; Chaft, J. E.; Nafa, K.; Roy Chowdhuri, S.; Lau, C.; Zaidinski, M.; Paik, P. K.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.
Clinical Cancer Research (2012)

Fulltext@MSK | Save